Key result
KTX-184 prevents cardiomyocyte hypertrophic remodelling by selectively degrading long PDE4D isoforms without altering contractility.
Why the study?
Selectively targeting disease-associated cAMP signalling remains challenging because conventional phosphodiesterase inhibitors offer limited isoform selectivity. Whether targeted degradation of long phosphodiesterase-4D (PDE4D) isoforms can suppress pathological cardiomyocyte growth while preserving contractile function was investigated.
Does targeted degradation of long PDE4D isoforms with the PROTAC KTX-184 attenuate pathological cardiomyocyte hypertrophy while preserving contractile function in rat and human myocardial models?
Does targeted degradation of long PDE4D isoforms with the PROTAC KTX-184 attenuate pathological cardiomyocyte hypertrophy while preserving contractile function in rat and human myocardial models?
Targeted PROTAC-mediated degradation of long PDE4D isoforms offers a spatially selective preclinical strategy to suppress cardiac hypertrophy without inducing positive inotropy or calcium-handling disturbances.
Answers are grounded in this paper and cite their sources.
Targeted long-PDE4D degradation may blunt hypertrophy without affecting contractility; hypothesis-generating for clinical translation from cardiomyocyte models.
Spatial compartmentalisation enables cyclic AMP (cAMP) to regulate distinct cellular functions, yet selectively targeting disease-associated signalling remains challenging. Phosphodiesterases constrain local cAMP responses, but conventional inhibitors offer limited isoform selectivity. Here we investigate whether targeted degradation of long phosphodiesterase-4D (PDE4D) isoforms can suppress pathological growth while preserving contractile function. Using adult rat and human ventricular cardiomyocytes and human myocardial slices, we show that the proteolysis-targeting chimera KTX-184 enhances compartmentalised cAMP signalling and attenuates hypertrophic remodelling. In rat cardiomyocytes, KTX-184 increases β-adrenergic cAMP responses in the cytosol and at the plasma membrane, including T-tubule and crest regions, and enhances nuclear protein kinase A activity. In contrast, phospholamban- and ryanodine receptor-associated cAMP nanodomains, calcium transients and sarcomere shortening remain unchanged. KTX-184 prevents angiotensin II-induced hypertrophic remodelling, preserves T-tubule organisation and normalises hypertrophic marker expression. In human cardiomyocytes, it increases cytosolic cAMP responses and prevents overload-induced hypertrophy in myocardial slices. These findings identify long PDE4D isoforms as targets for spatially selective modulation of cAMP signalling and support targeted degradation as an approach to suppress cardiac hypertrophy without increasing contractility.
No takes yet. Share an insight, caveat, or question.
Judina et al. (2026) studied Cardiac hypertrophy. KTX-184 (long-PDE4D PROTAC degrader) vs. Vehicle (0.1% DMSO) and apremilast (1 nmol/L or 100 nmol/L) was evaluated on Compartmentalised cAMP/PKA signalling and attenuation of cardiomyocyte hypertrophic remodelling. KTX-184 selectively degraded long PDE4D isoforms, enhanced compartmentalised cAMP/PKA signalling, and prevented hypertrophic remodelling in rat and human cardiomyocytes without altering contractility.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: